Professional Documents
Culture Documents
1
Hotchkiss, R. S., Moldawer, L. L., Opal, S. M., Reinhart, K., Turnbull, I. R., & Vincent, J. L. (2016). Sepsis and
2
septic shock. Nature Reviews Disease Primers, 2(1). https://doi.org/10.1038/nrdp.2016.45
Hotchkiss, R. S., Moldawer, L. L., Opal, S. M., Reinhart, K., Turnbull, I. R., & Vincent, J. L. (2016). Sepsis and 3
septic shock. Nature Reviews Disease Primers, 2(1). https://doi.org/10.1038/nrdp.2016.45
Hotchkiss, R. S., Moldawer, L. L., Opal, S. M., Reinhart, K., Turnbull, I. R., & Vincent, J. L. (2016). Sepsis and
4
septic shock. Nature Reviews Disease Primers, 2(1). https://doi.org/10.1038/nrdp.2016.45
5
JAMA Sepsis review 2016 Feb 315(a) 801
JAMA Sepsis review 2016 Feb 315(a) 801 6
Hotchkiss, R. S., Moldawer, L. L., Opal, S. M., Reinhart, K., Turnbull, I. R., & Vincent, J. L. (2016). Sepsis and
7
septic shock. Nature Reviews Disease Primers, 2(1). https://doi.org/10.1038/nrdp.2016.45
JAMA Sepsis review 2016 Feb 315(a) 801-2013
8
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine 9
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine 10
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine 11
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine 12
• Global Increased Permeability Syndrome
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine 13
Hotchkiss, R. S., Moldawer, L. L., Opal, S. M., Reinhart, K., Turnbull, I. R., & Vincent, J. L. (2016). Sepsis and
14
septic shock. Nature Reviews Disease Primers, 2(1). https://doi.org/10.1038/nrdp.2016.45
Hotchkiss, R. S., Moldawer, L. L., Opal, S. M., Reinhart, K., Turnbull, I. R., & Vincent, J. L. (2016). Sepsis and
15
septic shock. Nature Reviews Disease Primers, 2(1). https://doi.org/10.1038/nrdp.2016.45
SCCM | Surviving Sepsis Campaign Guidelines 2021.
16
(n.d.). Society of Critical Care Medicine
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine 17
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine 18
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine 19
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine 20
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine 21
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine 22
23
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine
24
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine
25
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine
26
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine
27
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine
28
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine
Como guiar el tratamiento en Sepsis!
29
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine
30
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine
31
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine
32
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine
33
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine
34
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine
35
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine
36
SCCM | Surviving Sepsis Campaign Guidelines 2021. (n.d.). Society of Critical Care Medicine
37
Bibliografía
1. Hotchkiss, R. S., Moldawer, L. L., Opal, S. M., Reinhart, K., Turnbull, I. R., & Vincent, J. L. (2016). Sepsis and septic shock. Nature Reviews
Disease Primers, 2(1). https://doi.org/10.1038/nrdp.2016.45
2. Singer M, Deutschman CS, Seymour CW, et al: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA
2016; 315:801–810
3. Fleischmann C, Scherag A, Adhikari NK, et al; International Forum of Acute Care Trialists: Assessment of global incidence and mortality of
hospital treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 2016; 193:259–272
4. Fleischmann-Struzek C, Mellhammar L, Rose N, et al: Incidence and mortality of hospital- and ICU-treated sepsis: Results from an updated
and expanded systematic review and meta-analysis. Intensive Care Med 2020; 46:1552–1562
5. Rhodes A, Evans LE, Alhazzani W, et al: Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock:
2016. Crit Care Med 2017; 45:486–552
6. Weiss SL, Peters MJ, Alhazzani W, et al: Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-
associated organ dysfunction in children. Intensive Care Med 2020; 46(Suppl 1):10–67
7. Shimabukuro DW, Barton CW, Feldman MD, et al: Effect of a machine learning-based severe sepsis prediction algorithm on patient
survival and hospital length of stay: A randomised clinical trial. BMJ Open Respir Res 2017; 4:e000234
38
Gracias!
39
Inotropic agents in cardiogenic and septic shock. E. Polyzogopoulou et al. Curr Opin Crit Care 2020, 26:403–410
40
41
42
Clasificación de agentes vasoactivos
43
Journal of Cardiovascular Pharmacology and Therapeutics 20(3)
Respuesta vascular a medicamentos vasoactivos
44
Journal of Cardiovascular Pharmacology and Therapeutics 20(3)
45
Inotropic agents in cardiogenic and septic shock. E. Polyzogopoulou et al. Curr Opin Crit Care 2020, 26:403–410
Inoconstrictores
51
Journal of Cardiovascular Pharmacology and Therapeutics 20(3)
Norepinefrina:
►Catecolamina endógena
►Neuronas simpáticas
►CVC: Potencial necrosis de piel y desprendimiento de tejido
►0,2 a 1 mg/kg/min
►Superior a dopamina: mayor supervivencia en shock cardiogénico y
shock séptico.
Inotropes. Gary S. Franci et al. JACC Vol. 63, No. 20, 2014
52
Inotropic agents in cardiogenic and septic shock. E. Polyzogopoulou et al. Curr Opin Crit Care 2020, 26:403–410
Noradrenalina
Inoconstrictores
Inotropic agentsCurrent
in cardiogenic
Status of
andInotropes
septic shock.
in Heart
E. Polyzogopoulou
Failure. M. Ginwalla,
et al.D.
Curr
S Tofovic
Opin Crit
et al.
CareHeart
2020,
Fail
26:403–410
Clin. 2018
56
Oct;14(4):601-616
Dobutamina:
Inotropic agents in cardiogenic and septic shock. E. Polyzogopoulou et al. Curr Opin Crit Care 2020, 26:403–410
57
Milrinone: ► bipiridina, sin catecolaminas
► 1990
► vasodilatador periférico
Inotropes. Gary S. Franci et al. JACC Vol. 63, No. 20, 2014
58
Milrinone:
Current Status of Inotropes in Heart Failure. M. Ginwalla, D. S Tofovic et al. Heart Fail Clin. 2018
59
Oct;14(4):601-616
Milrinone:
Inotropic agents in cardiogenic shock. E. Polyzogopoulou et al. Curr Opin Crit Care 2020,
60
26:403–410
Levosimendan:
► Sensibilidad de la troponina C al calcio
Sensibilizador de Ca+ intracelular.
► Aumenta la inotropía y la lusitropía
cardíacas
► Vasodilatación periférica
► Musc. Liso: Canales K+ ( ATP)
► Act. inhibidora de la PDE-3.
► No aumento de Ca+ o AMPc
►Dosis 4 h desde 0,1
mg/kg/min hasta 0,4
mg/kg/min y se mantiene
durante varias horas.
61
Levosimendan:
Current Status of Inotropes in Heart Failure. M. Ginwalla, D. S Tofovic et al. Heart Fail Clin. 2018
63
Oct;14(4):601-616
Levosimendan:
Inotropic agents in cardiogenic shock. E. Polyzogopoulou et al. Curr Opin Crit Care 2020,
64
26:403–410
► Ensayo de fase 3, multicéntrico, aleatorizado,
doble ciego. controlado con placebo,
► >18 años
► FEVI < 35% 🡪 cirugía cardíaca con el uso de
circulación extracorpórea
► Levosimendan 0,2 μg/kg/min (1 hora)🡪0,1
μg /kg/min (23 horas) Vs placebo
Current Status of Inotropes in Heart Failure and sepsis. M. Ginwalla, D. S Tofovic et al. Heart
66
Fail Clin. 2018 Oct;14(4):601-616
Dopamina:
DOSIS
<3 activa los
vasodilatación:
arterias coronaria
No mejoria de
mcg/kg/min receptores (D1)
y renal.
TFG,
Liberación e
receptores β-
3 a 10 adrenérgicos:
inhiben la
recaptación de
mcg/kg/min aumentan
inotropismo y FC
NE simpáticas
presinápticas
10 a 20 agonista a-
Vasoconstricción
mcg/kg/min adrenérgico
Inotropes. Gary S. Franci et al. JACC Vol. 63, No. 20, 2014
68
Inotropes in Patients with Advanced Heart Failure, Masarone et al. Heart Failure Clin 17 (2021)
69
587–598